ArticleJournal of psychopharmacology (Oxford, England)2021
Neuropsychological performance in young adults with cannabis use disorder.
Article in Journal of psychopharmacology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society.Journal of psychopharmacology (Oxford, England) · 2026Article
- Brain reward function in people with moderate-to-severe cannabis use disorder who tried to cut down or quit: an fMRI study.Scientific reports · 2026Article
- Regular cannabis use modulates gamma functional connectivity with V1 during visual processing.NeuroImage · 2025Article
- Network topology and cannabis use following two weeks of monitored abstinence: moderation of sex and patterns of use findings.Frontiers in adolescent medicine · 2025Article
- Regular cannabis use modulates gamma activity in brain regions serving motor control.Journal of psychopharmacology (Oxford, England) · 2024Article
- Genetic influences and causal pathways shared between cannabis use disorder and other substance use traits.Molecular psychiatry · 2024Article
- Chronic Pain and Cannabis Use Frequency, Intensity, and Severity in Young Adults.Substance use & misuse · 2024Article
- Ratings of executive function as a risk factor for adolescents' frequent cannabis use: A prospective longitudinal study.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023Article
- Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study.Brain : a journal of neurology · 2023Article
- Article
- Marijuana use in children: An update focusing on pediatric tetrahydrocannabinol and cannabidiol use.Journal of the American College of Emergency Physicians open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsCannabis is a commonly used recreational drug in young adults. The worldwide prevalence in 18- to 25-year-olds is approximately 35%. Significant differences in cognitive performance have been reported previously for groups of cannabis users. However, the groups are often heterogeneous in terms of cannabis use. Here, we study daily cannabis users with a confirmed diagnosis of cannabis use disorder (CUD) to examine cognitive performance on measures of memory, executive function and risky decision-making.
methodsForty young adult daily cannabis users with diagnosed CUD and 20 healthy controls matched for sex and premorbid intelligence quotient (IQ) were included. The neuropsychological battery implemented was designed to measure multiple modes of memory (visual, episodic and working memory), risky decision-making and other domains of executive function using subtests from the Cambridge Neuropsychological Test Automated Battery (CANTAB).
resultsOur results showed that young adult daily cannabis users with CUD perform significantly poorer on tasks of visual and episodic memory compared with healthy controls. In addition, executive functioning was associated with the age of onset.
conclusionsFurther research is required to determine whether worse performance in cognition results in cannabis use or is a consequence of cannabis use. Chronic heavy cannabis use during a critical period of brain development may have a particularly negative impact on cognition. Research into the persistence of cognitive differences and how they relate to functional outcomes such as academic/career performance is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.